Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings, Inc. Class A (RANI)
NASDAQ:RANI
RANI Stock Chart & Stats
$1.27
-$0.04(-3.15%)
At close: 4:00 PM EST
$1.27
-$0.04(-3.15%)
Day’s Range― - ―
52-Week Range$0.39 - $3.87
Previous CloseN/A
Volume228.85K
Average Volume (3M)873.76K
Market Cap
$165.27M
Enterprise Value$114.14M
Total Cash (Recent Filing)$4.14M
Total Debt (Recent Filing)$17.55M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Mar 25, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding97,550,980
10 Day Avg. Volume724,898
30 Day Avg. Volume873,757
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)19.58
Price to Sales (P/S)37.95
P/FCF Ratio-1.09
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue95.12
Enterprise Value/Gross Profit116.83
Enterprise Value/Ebitda-2.66
Forecast
1Y Price Target
$10.50Price Target Upside726.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$6.75M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAnalyst views initiation of a Phase 1 study for RT-114 as a meaningful clinical milestone that advances the company toward a potential oral obesity therapy.
Delivery TechnologyAnalyst highlights the RaniPill oral delivery platform as a potential way to deliver GLP-based medicines at doses comparable to injectables, addressing poor bioavailability of current oral approaches.
Financial PositionAnalyst notes that the company holds sufficient cash to support internal pipeline development for multiple years, reducing near-term financing pressure and improving strategic optionality.
Bears Say
Efficacy PotentialAnalyst warns that RT-114 is unlikely to match the highest weight-loss levels of the most potent drugs in the class, which could limit adoption among patients seeking maximal results.
Partnering RiskAnalyst highlights partnering risk as a key concern, noting that failure to secure strategic collaborators could slow development, commercialization, or market access.
Regulatory RiskAnalyst flags clinical development and regulatory uncertainty as material risks that could delay progress or prevent approval of RT-114.
Rani Therapeutics Holdings News
RANI FAQ
What was Rani Therapeutics Holdings, Inc. Class A’s price range in the past 12 months?
Rani Therapeutics Holdings, Inc. Class A lowest stock price was $0.39 and its highest was $3.87 in the past 12 months.
What is Rani Therapeutics Holdings, Inc. Class A’s market cap?
Rani Therapeutics Holdings, Inc. Class A’s market cap is $165.27M.
When is Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date?
Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date is Mar 25, 2026 which is in 21 days.
How were Rani Therapeutics Holdings, Inc. Class A’s earnings last quarter?
Rani Therapeutics Holdings, Inc. Class A released its earnings results on Nov 06, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.152 by $0.032.
Is Rani Therapeutics Holdings, Inc. Class A overvalued?
According to Wall Street analysts Rani Therapeutics Holdings, Inc. Class A’s price is currently Undervalued.
Does Rani Therapeutics Holdings, Inc. Class A pay dividends?
Rani Therapeutics Holdings, Inc. Class A does not currently pay dividends.
What is Rani Therapeutics Holdings, Inc. Class A’s EPS estimate?
Rani Therapeutics Holdings, Inc. Class A’s EPS estimate is -0.05.
How many shares outstanding does Rani Therapeutics Holdings, Inc. Class A have?
Rani Therapeutics Holdings, Inc. Class A has 97,550,980 shares outstanding.
What happened to Rani Therapeutics Holdings, Inc. Class A’s price movement after its last earnings report?
Rani Therapeutics Holdings, Inc. Class A reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.152. Following the earnings report the stock price went down -11.013%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings, Inc. Class A?
Currently, no hedge funds are holding shares in RANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rani Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (726.77% Upside)
$10.50 (726.77% Upside)
Blogger Sentiment
Bullish
RANI Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-76.71%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
RANI Stock 12 Month Forecast
Average Price Target
$10.50
▲(726.77% Upside)
Technical Analysis
Tenax Therapeutics
―
Iterum Therapeutics
―
Annovis Bio
―
PolyPid
―
AN2 Therapeutics, Inc.
―
Ownership Overview
29.28% Insiders
1.07% Mutual Funds
16.88% Other Institutional Investors
47.75% Public Companies and Individual Investors
Options Prices
Currently, No data available
---